Clinical Trial Update: Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 non-inferiority trial comparing ocrelizumab with rituximab in active multiple sclerosis is described; the study is currently active but not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Ocrevus (ocrelizumab)
• Rituxan (rituximab)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING